Research Article
Second-Line Antiretroviral Treatment Outcome in HIV-Infected Patients Coinfected with Tuberculosis in Pakistan
Table 2
Clinico-immunological and virological outcome in HIV patients on 2nd-line ART coinfection with or without TB.
| | S. No. | Characteristic/risk factor | Total patient No. (%) | HIVPosTBPos patient No. (%) | HIVPosTBNeg patient No. (%) | value |
| | 1 | Adherence to 2nd-line ART | | <95% | 15 (20.3%) | 6 (40.0%) | 9 (60.0%) | — | | ≥95% | 59 (79.7%) | 27 (45.8%) | 32 (54.2%) | 0.688 | | 2 | NRTI combination in 2nd-line regimen initiated | | Tenofavir based | 49 (66.2%) | 22 (44.9%) | 27 (55.1%) | — | | Non-Tenofavir based | 25 (33.8%) | 11 (44.0%) | 14 (56.0%) | 0.941 | | 3 | ARV side effect during 2nd-line ART | | 13 (17.6%) | 8 (61.5%) | 5 (38.5%) | 0.176 | | 4 | ARV switching during 2nd-line ART | | 9 (12.2%) | 7 (77.8%) | 2 (22.2%) | 0.033 | | 5 | Opportunistic infections other than TB | | 50 (67.6%) | 26 (52.0%) | 24 (48.0%) | 0.064 | | 6 | Clinical outcome | | Death | 9 (12.2%) | 6 (66.7%) | 3 (33.3%) | — | | LTFU | 1 (1.4%) | 1 (100%) | 0 | — | | Alive | 64 (86.5) | 26 (40.6%) | 38 (59.4%) | 0.180 | | 7 | Virological failure while on 2nd-line ART | | 29 (39.2%) | 13 (44.8%) | 16 (55.2%) | 0.974 | | 8 | CD4 at 12 months of 2nd-line ART (cells/mm3) | | Total | — | | | 0.334 | | <200 | 14 (18.9%) | 6 (42.9%) | 8 (57.1%) | — | | ≥200 | 60 (81.1%) | 27 (45%) | 33 (55%) | 0.885 | | 9 | CD4 gain after 2nd-line ART of 12 months (cells/mm3) | | Total | — | | | 0.741 | | <100 | 19 (25.7%) | 7 (36.8%) | 12 (63.2%) | — | | ≥100 | 55 (74.3%) | 26 (47.3%) | 29 (52.7%) | 0.303 | | 10 | VL after 2nd-line ART of 12 months (copies/ml) | | Total | — | | | 0.551 | | <1000 | 52 (70.3%) | 23 (44.2%) | 29 (55.8%) | — | | ≥1000 | 22 (29.7%) | 10 (45.5%) | 12 (54.5%) | 0.923 |
|
|
NRTI: nucleoside reverse transcriptase inhibitors; ARV: antiretroviral; LTFU: loss to follow-up. |
